NFL Biosciences SA (EPA:ALNFL)

France flag France · Delayed Price · Currency is EUR
1.078
+0.006 (0.56%)
At close: Mar 6, 2026
-35.45%
Market Cap 13.66M
Revenue (ttm) 164.00
Net Income (ttm) -3.15M
Shares Out 12.67M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 19,015
Average Volume 55,034
Open 1.090
Previous Close 1.072
Day's Range 1.062 - 1.096
52-Week Range 0.851 - 1.860
Beta 1.26
RSI 40.21
Earnings Date Apr 15, 2026

About NFL Biosciences

NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company’s pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding of the mechanism of action of NFL-101, its proprietary botanical drug candidate for smoking cessation. NFL Biosciences SA was incorporated in 2006 and... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 5
Stock Exchange Euronext Paris
Ticker Symbol ALNFL
Full Company Profile

Financial Performance

In 2024, NFL Biosciences's revenue was 46, a decrease of -99.98% compared to the previous year's 200,011. Losses were -2.08 million, -44.44% less than in 2023.

Financial Statements

News

There is no news available yet.